Domzalski David 4

What Happened
David Domzalski, President & CEO and a director of VYNE Therapeutics (VYNE), acquired 30,791 shares on May 29, 2026 under the issuer's Employee Stock Purchase Plan (ESPP). The shares were purchased at $0.31 per share for a total cost of $9,545. This was an acquisition (purchase) rather than a sale.

Key Details

• Transaction date: 2026-05-29; price: $0.31 per share; total value: $9,545.
• Transaction type/code: Acquisition under ESPP (reported as code A).
• ESPP offering period: December 1, 2025 – May 31, 2026 (purchase made at 85% of the fair market value on Dec 1, 2025).
• Filing notes: Transaction was exempt under Rule 16b-3(d) and Rule 16b-3(c) (typical for ESPP purchases by insiders). The reporting person purchased the maximum number of shares permitted by the ESPP for the calendar year.
• Shares owned after transaction: not disclosed in the provided filing.

Context
This was a discounted ESPP purchase (employees often buy at a set discount to a prior-date FMV); such purchases are routine compensation-related acquisitions and are generally viewed differently than open-market buys. The filing is informational and does not state any intent or market-view by the insider.